An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Phase I dose escalation study (n=45) found that a candidate vaccine, mRNA-1273, induced anri-SARS-CoV-2 immune responses in all participants and no trial-limiting safety concerns were identified, supporting the further development of this vaccine.

SPS commentary:

A related editorial notes that accelerating the development of Covid-19 vaccine candidates beyond phase 1 depends on continued parallel tracking of activities and fulsome resources. It concludes that the world has now witnessed the compression of 6 years of work into 6 months. It questions whether the vaccine multiverse do it again, leading to a reality of a safe, efficacious Covid-19 vaccine for the most vulnerable in the next 6 months.


New England Journal of Medicine

Resource links: